AstraZeneca has sold off European rights for two heart failure drugs to Germany specialty pharma Cheplapharm, shedding Atacand and Atacand Plus from its portfolio in 28 European countries in exchange for $200 million upfront.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,